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Abstract
The growth in knowledge of the pathogenesis, molecular background, and immunohistochemical profile of neuroendocrine 
neoplasms (NENs) has led not only to an increased awareness of these diseases but also to several changes of the nomenclature. 
In particular, the concept and terminology of high-grade (grade 3) NENs and mixed neoplasms have changed considerably 
over the last 20 years, creating some confusion among pathologists and clinicians. The aim of this review is to elucidate the 
diagnostic criteria, including the most important differential diagnoses of high-grade NENs and mixed neuroendocrine/non-
neuroendocrine neoplasms (MiNENs). The role of the Ki67 labelling index and morphology, used to define grade 3 NENs 
of the digestive system and lungs, is also discussed. The evolution of the concepts and terminology of MiNENs is revised, 
including the most important differential diagnoses.
Keywords Neuroendocrine tumor · High grade · Ki67 · Neuroendocrine carcinoma · MiNEN · Diagnosis
Introduction
The last 20 years have seen considerable growth in the 
knowledge of neuroendocrine neoplasms (NENs) leading 
not only to an increased awareness of these diseases but 
also to several changes in the nomenclature, mainly due to a 
better understanding of their pathogenesis, molecular back-
ground, and clinical behavior. Although this evolution has 
clearly improved patient management, it has created some 
confusion among pathologists and clinicians, especially if 
not working in referral centers dedicated to neuroendocrine 
pathology. The concepts and terminology of high-grade 
NENs and mixed neoplasms have changed considerably. 
Hence, the aim of this review is to elucidate their diagnostic 




Although NENs have been well known since 1907, when 
Oberndorfer introduced the term “carcinoid” [1], the con-
cept of high-grade NENs is more recent and has been bet-
ter developed during the last 15 years (Fig. 1). In 1994, the 
first prognostic classification of NENs was proposed, and 
poorly differentiated neuroendocrine carcinomas were clearly 
separated from well differentiated neuroendocrine tumors to 
underline their different biological aggressiveness and prog-
nosis [2]. Since then, the term high-grade NEN has been 
synonymous with poorly differentiated neuroendocrine car-
cinoma. It was only in 2006, 100 years after the introduction 
of the term carcinoid, that the concept of grade for diges-
tive NENs was proposed by the European Neuroendocrine 
Tumor Society (ENETS). It was based on cell proliferation 
and evaluated using mitotic count and the Ki67 proliferative 
index [3, 4]. Based on the growing body of evidence concern-
ing the prognostic importance of proliferation [5], the WHO 
classification of digestive NENs, published in 2010, adopted 
the ENETS’ three-tiered grading system, with the first two 
grades (G1 and G2) being included in the well differentiated 
tumor categories and G3 representing poorly differentiated 
neuroendocrine carcinomas (NEC) [6]. A weak point of this 
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approach was the complete apparent overlap between mor-
phological differentiation and proliferation grading, which 
was revealed to be a critical point. Indeed, the existence 
of morphologically well differentiated NENs, called neu-
roendocrine tumors (NETs), with a high proliferation index 
(mitotic count > 20 mitoses/2  mm2 and/or Ki67 index > 20%, 
grade 3) was not included in the 2010 WHO classification 
[6]. However, starting from clinical observations [7], it soon 
became evident that NENs with a high proliferation index 
(high-grade NENs) are morphologically, clinically, and bio-
logically heterogeneous [8–11]. Consequently, the concept of 
NET G3 (well differentiated tumors with high proliferation) 
was successively integrated into the WHO classifications of 
GEP neoplasms, leaving the definition of NEC to NENs with 
poorly differentiated morphology [12, 13]. Similar observa-
tions have been described in thoracic sites [14], where a pro-
liferative grading system has still not been officially adopted 
in the WHO classification [15]. The fact that NETs (including 
NET G3) and NECs are distinct clinico-pathological entities 
has been supported for a long time [16], and molecular find-
ings have confirmed this assumption, showing that these two 
families of neoplasms follow different pathogenetic pathways 
[17]. However, very recent evidence suggests that a subgroup 
of large cell neuroendocrine carcinomas probably arise from 
pre-existing NETs in both respiratory and digestive systems 
[14, 18, 19], although this phenomenon needs to be better 
explored.
High‑grade NENs of the Digestive System
Definition and Diagnostic Criteria
By definition, high-grade NENs include neoplasms of pro-
liferative grade 3, characterized by a mitotic count > 20 
mitoses/2   mm2 and/or a Ki67 proliferative index > 20%. 
Morphologically, they can be either well differentiated (NET 
G3) or poorly differentiated (NEC) (Table 1). This distinc-
tion is fundamental due to their different prognoses (median 
overall survival of 33 months for NETs G3 versus 11 months 
for NECs) [9, 20], clinical presentation, functional imaging 
characterization, and different therapeutic approaches [21, 
22]. Indeed, NETs G3 can generally be identified by soma-
tostatin receptor imaging, whereas in NECs, which show 
loss of morphological differentiation and increase of pro-
liferation, 18F-FDG represents the best imaging procedure 
[21]. NETs G3 are generally treated like the more common 
NETs G2 using different approaches, which include surgery 
(for localized disease) and different medical options such as 
chemotherapy, everolimus, and peptide receptor radionucle-
otide therapy (PRRT). Conversely, surgery has a limited role 
for NECs, while the treatment of choice is platinum-based 
chemotherapy [21, 22].
NETs G3 are histologically characterized by an orga-
noid proliferation of rather uniform cells, with moderately 
abundant granular and eosinophilic cytoplasm. Nuclei are 
Fig. 1  Timeline of the evolution of the concept of high-grade neuroendocrine neoplasms of the digestive system. ENETS, European Neuroendo-
crine Tumor Society; NEN, neuroendocrine neoplasm; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma
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generally round, with finely granular (“salt and pepper”) 
chromatin and small nucleoli, more prominent in some 
cases. Nuclear atypia may be up to moderate in some cases. 
Vascular and lymphatic invasion is frequently observed 
as well as perineural invasion. By definition, these NETs 
show high proliferation including > 20 mitoses/2  mm2 or, 
more frequently, a Ki67 proliferative index > 20%. The Ki67 
index seems more reliable for defining NETs G3, which 
although higher than 20%, generally do not exceed 55–60% 
as observed in NECs. Tumor cells are positive for general 
neuroendocrine markers including synaptophysin, chro-
mogranin A, and INSM1. They also express somatostatin 
receptor 2A and can be positive for CDX2, ISL1, PDX1, 
and different hormones (i.e., insulin, glucagon, somatostatin, 
pancreatic polypeptide, gastrin, serotonin, substance P, gli-
centin, and PYY) depending on the site of origin [16]. The 
role of immunohistochemistry for transcription factors and 
hormones is useful for the correct characterization of these 
neoplasms and also for the identification of their primary 
site when they present as metastatic disease without a known 
primary origin [23]. Indeed, transcription factor and hor-
mone expression generally reflects the site of origin as sum-
marized in Table 2. It is worth noting that the expression of 
transcription factors in NECs does not reflect the origin and, 
consequently, cannot be used to identify the site of origin of 
metastatic occult NECs [23].
NECs are generally larger neoplasms showing deep 
infiltration of the bowel wall or of the peri-pancreatic 
Table 1  WHO classification 
of digestive neuroendocrine 
neoplasms [12, 13]
NET neuroendocrine tumor, NEC neuroendocrine carcinoma, MiNEN mixed neuroendocrine/non-neuroen-
docrine neoplasm
Morphological differentiation Proliferative grade Mitotic 
count/2  mm2
Ki67 index
NET G1 Well-differentiated Grade 1  < 2  < 3%
NET G2 Well-differentiated Grade 2 2–20 3–20%
NET G3 Well-differentiated Grade 3  > 20  > 20%
NEC Poorly differentiated Grade 3  > 20  > 20%
MiNENs Well or poorly differentiated Variable Variable Variable
Table 2  Correlation 
between the site of origin 
and transcription factor and 
hormone expression in lung and 
digestive well-differentiated 
neuroendocrine tumors (NETs)
TTF1 thyroid transcription factor-1, OTP orthopedia homeobox protein, CDX2 caudal type homeobox 2; 
PDX1 pancreatic and duodenal homeobox  1, ISL1 insulin gene enhancer binding protein Isl-1, VMAT 
vesicular monoamine transporter, PSAP prostatic acid phosphatase
*Not commercially available antibodies well working
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tissue (in the pancreas). Microscopically, they are char-
acterized by a solid proliferation of cells with large areas 
of “geographic chart” necrosis. They can be divided into 
the small and large cell subtypes, based on the morpho-
logical features of neoplastic cells. Small cell carcino-
mas (Fig. 2a) are composed of small to medium-sized 
(2–4 times the size of a small lymphocyte), round to 
oval cells with scant cytoplasm, indistinct cell borders, 
and hyperchromatic nuclei with inconspicuous nucleoli. 
Large cell subtypes (Fig. 2b) are composed of large cells 
with vesicular nuclei showing prominent nucleoli and 
abundant eosinophilic cytoplasm, which form a more 
structured organoid architecture than small cell NECs. 
In both large cell and small cell subtypes, mitotic figures 
are extremely frequent, as well as apoptotic bodies and 
vascular and perineural infiltration. The neuroendocrine 
nature needs to be confirmed by immunohistochemical 
analyses and includes the expression of general neuroen-
docrine markers: synaptophysin and INSM1 are generally 
well expressed, while chromogranin A can be negative 
or focally positive, typically showing a perinuclear dot-
like pattern of immunoreactivity. Tumor cells can express 
TTF1 and CDX2 irrespective of the site of origin and can 
be positive for ASH1 [16, 24].
Interestingly, the distribution of NETs G3 and NECs 
in the digestive system is different. NETs G3 have been 
more frequently observed in the pancreas [20]. They have 
also been described in the stomach, more commonly as 
a subgroup of type 3 NETs, although type 1 ECL-cell 
G3 NETs have also been rarely reported [25, 26]. They 
are rare in other digestive sites including the midgut and 
rectum [20]. Conversely, NECs seem to be more frequent 
than NETs G3 in the gut than in the pancreas and, in par-
ticular, in the rectum followed by the stomach [20, 25].
Mimickers and Differential Diagnosis
The correct diagnosis of a NET G3 and its differential diagnosis 
with G1/G2 NETs, NECs, or other non-neuroendocrine mimickers 
are fundamental for the specific therapeutic approaches of these 
different entities.
Due to the morphological overlap among NETs, irrespec-
tive of their grade, the diagnosis of NET G3 respect to NET 
G1 and G2 is based on the accurate evaluation of the Ki67 
proliferative index. Different methods for the evaluation of 
the Ki67 labelling index have been proposed and used in 
previous years. However, the manual count on a camera-
captured printed image appears to be the most reliable pro-
cedure [27, 28] and for this reason was officially proposed 
by the WHO [12]. In practice, the highest labeled area 
(“hot spot”) is selected, and a picture is taken and printed 
(Fig. 3a). All the Ki67-positive neoplastic nuclei need to be 
counted from this image, regardless of the staining inten-
sity or whether the nuclei show a speckled or a diffuse stain 
(Fig. 3b). The number of stained nuclei is then expressed 
as a percentage (“index”) of immunoreactive cells in 500 
to 1000 tumor cells. This method has been demonstrated to 
show good reproducibility and takes on average between 10 
and 15 min. Other methods have been proposed but do not 
seem to perform as well, as discussed elsewhere [5].
The differential diagnosis between NET G3 and small 
cell NEC is generally easy and based on the morphological 
characteristics of tumor cells and does not require specific 
and sophisticated additional techniques.
The differential diagnosis between NET G3 and large 
cell NEC (LCNEC) is first based on morphological 
grounds, once the neuroendocrine nature is confirmed 
by the appropriate immunohistochemical profile. It 
is generally easy due to the different morphological 
Fig. 2  The distinction between small cell A  and large cell B  neu-
roendocrine carcinoma is based on morphology. Small cell neuroen-
docrine carcinoma is composed of round to oval, small- to medium-
sized cells, measuring 2–4 times the size of a small lymphocyte. The 
cytoplasm is scant and the nuclei are hyperchromatic with incon-
spicuous nucleoli. Conversely, large cell neuroendocrine carcinomas 
are composed of large cells with vesicular nuclei showing prominent 
nucleoli and abundant eosinophilic cytoplasm
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characteristics of tumor cells (Fig. 4). However, in some 
cases, the morphology of NET G3 may be less clear 
showing “borderline” features including some nuclei 
with vesicular chromatin and evident nucleolus or show-
ing pleomorphic features (Fig. 5). In these cases, the 
use of additional immunohistochemical markers and/or 
molecular analysis is recommended. It is well known that 
the molecular background of NETs is different from that 
of NECs and this directly reflects the different expres-
sion of several markers [17, 29]. Indeed, the carcinogen-
esis of NECs is similar to that of non-neuroendocrine 
carcinomas of the primary site in which they arise and 
includes inactivation of TP53 and RB1 [17]. In contrast, 
NETs of the digestive system can present inactivation 
of MEN1, VHL, and TSC1/2 genes and the hyperactiva-
tion of the PI3K/mTOR pathway [29]. For these reasons, 
NETs G3 generally show a “wild-type” p53 expression 
and diffuse immunoreactivity for Rb protein in neoplastic 
nuclei, reflecting the absence of mutation in the relatives 
genes. ATRX and DAXX expression can be lost in about 
30% of pancreatic NETs as a consequence of their gene 
mutations as well as MEN1 protein expression. In addi-
tion to these markers, whose immunohistochemical 
expression strongly correlates with gene mutations, the 
expression of chromogranin A and somatostatin recep-
tor 2A can be different between NETs G3 and LCNECs 
[23]. Chromogranin A is strongly and diffusely positive 
in NETs, while it can be focal with a perinuclear “dot-
like” pattern of immunoreactivity in NECs. Somatosta-
tin receptor 2A shows strong membrane expression in 
NETs (score 3+ according to Volante et al.) [30], while 
in NECs, its expression can be focal and cytoplasmic, or 
even absent.
Among non-neuroendocrine mimickers, acinar cell 
carcinoma (ACC) represents an important potential pit-
fall when diagnosing a pancreatic NET G3. The mor-
phological suspicion of an ACC should be taken into 
account when a tumor showing a well-differentiated 
Fig. 3  Evaluation of Ki67 proliferative index by manual count on a 
camera-captured, printed image A. This field, selected at low power 
magnification, represents the highest labeled area (“hot spot”) of 
the tumor. On this image, all the Ki67-positive (marked in red) and 
Ki67-negative (marked in bleu) tumor nuclei were counted, excluding 
endothelial, stromal and lymphocytic cells B. 268 nuclei were Ki67 
positive on 1146 counted tumor nuclei, corresponding to a Ki67 pro-
liferative index of 23%
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neuroendocrine-like morphology presents areas of 
abundant necrosis, unexpected prominent nucleoli, very 
high mitotic count or Ki67 index, and focal or absent 
expression of general neuroendocrine markers (Fig. 6). 
In these cases, an additional immunohistochemical panel 
including BCL10 and trypsin is mandatory to confirm 
the diagnosis of ACC.
The differential diagnosis with an adenocarcinoma show-
ing a solid/organoid growth pattern should be considered 
when a neoplasm with a neuroendocrine-like morphology 
and composed of medium- to large-sized cells is completely 
negative for general neuroendocrine markers.
High‑grade NENs of the Lung
Definition and Diagnostic Criteria
The recognition and definition of high-grade carcinoids 
(NETs) in the lung are not as well established as in the diges-
tive system. Indeed, for years, the classification of lung NETs 
(carcinoids), also including their distinction from LCNECs, 
has been based on morphological criteria, which included 
mitotic count and the presence of necrosis. The Ki67 pro-
liferative index was only introduced in the last WHO clas-
sification of lung NENs as an ancillary marker useful in the 
diagnostic work-up of lung or bronchial biopsies [15]. How-
ever, the Ki67 proliferative index has progressively emerged 
as a relevant prognostic indicator in lung carcinoids [31] and, 
consequently, its assessment has been strongly recommended 
[32]. In line with these observations, Rindi and coworkers 
proposed a prognostic grading system, which, in addition to 
mitotic index and necrosis, included Ki67 index [33]. How-
ever, this grading system has not been universally accepted 
[34], although its clinical value also appeared useful in the 
pre-operative setting [35]. Irrespective of the integration of 
Ki67 into a grading system, an increasing body of evidence has 
demonstrated that a high Ki67 index (using a cutoff of 10% or 
25%) identifies a subgroup of lung carcinoids (NETs) with a 
worse outcome, which is unrelated to their typical or atypical 
subtype. It has been suggested that these cases may represent 
the lung counterpart of the well-known digestive “NET G3,” 
since they retain a well differentiated morphology associated 
with high mitotic and Ki67 index (Fig. 7) in the absence of 
RB1 and TP53 alterations [36–38]. With respect to the diges-
tive system, the Ki67 cutoffs of 10% and 25% seem better at 
separating NET G1 from NET G2 and NET G2 from NET 
G3, respectively [39]. Taken together, these findings support 
Fig. 4  Morphological fea-
tures useful for differentiating 
between grade 3 neuroendocrine 
tumors (NET G3) and large cell 
neuroendocrine carcinomas 
(LCNEC)
Fig. 5  This NET G3 shows some clear nuclei with evident nucleoli 
in the absence of necrosis and true vesicular and large nuclei with 
prominent eosinophilic nucleoli. This “borderline cell morphology” 
renders the differential diagnosis with a large cell neuroendocrine car-
cinoma difficult. In similar cases, the use of additional immunohisto-
chemical and/or molecular analyses is useful (see the text)
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Fig. 6  Pancreatic acinar cell carcinomas may simulate a NET G3. 
This is an example of a pancreatic neoplasm with neuroendocrine-
like features including a trabecular pattern of growth A. However, 
in some areas, abundant necrosis is observed B  and at high power 
magnification tumor cells show nuclei with prominent nucleoli C and 
high mitotic count D. In addition, a high Ki67 index is found E and 
neuroendocrine markers are lacking (F, synaptophysin). All these 
features should suggest the possible differential diagnosis with an 
acinar cell carcinoma, and an immunohistochemical analysis includ-
ing BCL10 and trypsin is mandatory. This case was positive for both 
acinar cell markers, and the final diagnosis was acinar cell carcinoma
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the hypothesis that, similarly to the digestive system, thoracic 
NENs can include NETs with different grades (from G1 to G3) 
and NECs of large and small cell subtypes that fall into the 
poorly differentiated category and show a Ki67 index > 55% 
(Table 3) [39].
Mimickers and Differential Diagnosis
Although still not considered as a separate entity as in the 
digestive system, lung carcinoids (NETs) with high prolif-
eration, which can be provisionally considered “lung NETs 
G3,” need to be recognized for their worse prognosis than 
not highly proliferative carcinoids and better prognosis 
than LCNECs. The distinction from “low proliferative” 
carcinoid types is based on the count of Ki67-positive 
nuclei. Although standardized criteria to evaluate the Ki67 
index have not been validated for lung NETs, it appears 
reasonable that the same system for the evaluation of the 
Ki67 proliferative index validated in the digestive system 
can be used (see the specific paragraph above). Conse-
quently, despite similar morphological features, lung G3 
NETs can easily be identified and separated from G1 and 
G2 NETs using Ki67 immunohistochemistry. The distinc-
tion of G3 NETs from LCNECs may be more problematic 
Fig. 7  NET G3 of the lung. This tumor, defined as atypical carcinoid 
following the WHO criteria [7], shows a trabecular architecture and is 
composed of well differentiated cells. Two mitoses (arrows) are pre-
sent in this field A. Tumor cells are positive for synaptophysin B and 
the Ki67 proliferative index is higher than 25% C. Immunohisto-
chemistry for p53 shows scattered and weak positive nuclei
Table 3  Proposal of a 
prognostic classification of lung 
neuroendocrine neoplasms [39]
Morphological differentiation Ki67 proliferative index Proposed 
terminology
WHO terminology [7]
Well differentiated Ki67 ≤ 10% NET G1 Typical carcinoid—frequent
Atypical carcinoid—rare
Well differentiated 10% < Ki67 ≤ 25% NET G2 Typical carcinoid—rare
Atypical carcinoid—frequent
Well differentiated 25% < Ki67 ≤ 55% NET G3 Atypical carcinoid
Poorly differentiated Ki67 > 55% NEC Large or small cell NECs
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in some cases and the use of molecular tests can be of 
help, namely the search for RB1 or TP53 mutations. It is 
worth noting that LCNECs generally show a Ki67 prolif-
erative index higher than 50–60%, which is rarely found 
in carcinoids.
MiNENs
Evolution of Their Understanding and Definition
Neoplasms showing the coexistence of a neuroendocrine and 
a non-neuroendocrine component have been described in 
almost all organs of the human body and have been a matter 
of investigation during the last 20 years. In particular, their 
clinical relevance has increased since the use of immuno-
histochemistry has been largely introduced in the work-up 
of tumors, facilitating the possibility of their identification 
with a consequent increase in diagnosis.
Their terminology as well as their inclusion in the WHO 
classifications of tumors of different sites have been a mat-
ter of discussion for years. Indeed, different terms have 
been used for defining mixed neoplasms composed of both 
neuroendocrine and non-neuroendocrine components cre-
ating some confusion. Although described in all systems, 
they have been better characterized and investigated in the 
digestive system, where they were called “mixed endocrine-
exocrine tumors” (MEEC) in the WHO classification pub-
lished in 2000 [40]. In 2010, the term MEEC was replaced 
by the term “mixed adenoneuroendocrine carcinoma” 
(MANEC) [6], which was criticized in subsequent years. 
The most important weak point of this terminology resides 
in the fact that it states that all neoplasms are composed of 
adenocarcinomas and NECs; although this represents the 
most frequent association, it does not encompass the large 
spectrum of possible combinations. Indeed, both neuroen-
docrine and non-neuroendocrine components can show vari-
able morphological features: NECs or NETs can represent 
the neuroendocrine component, while the histological fea-
tures of the non-neuroendocrine component depend on the 
site of origin (adenocarcinoma, squamous cell carcinoma, 
acinar cell carcinoma, etc.). In addition, the term MANEC 
cannot be applied to mixed neoplasms arising in other sys-
tems, including endocrine and non-endocrine organs like 
the pituitary gland, lung, skin, and those of the urogenital 
system and head and neck region. To cover this wide spec-
trum of different mixed neoplasms, also showing some site-
related peculiarities, in 2016, we proposed the simple and 
general term “mixed neuroendocrine/non-neuroendocrine 
neoplasm (MiNEN)” [41]. This term has the advantage of 
being used for diagnosing mixed neoplasms arising in dif-
ferent organs and resulting from the combination of different 
components. Consequently, it can be used as a diagnostic 
term in pathology reports, with the addition of a detailed 
description of the two neoplastic components to provide the 
clinician with the prognostic information useful for choosing 
the most appropriate therapy. The term MiNEN has been 
accepted and is in use for the diagnosis of mixed neoplasms 
arising in the digestive system [12, 13]. However, it has not 
been officially accepted for mixed neoplasms arising in other 
sites including prostate, urinary bladder, and kidney [42]. In 
addition, such mixed neoplasms are not classified as sepa-
rated entities in several organs, where they are included as 
subtypes of neuroendocrine carcinomas due to the similar 
clinical behavior (i.e., in the lung and larynx) [15, 43] or 
are not classified at all due to their rarity (for example in the 
nasal cavity, pituitary gland or skin) [43–45]. We suggest 
that the term MiNEN could also be used to define mixed 
neoplasms arising in non-digestive organs, in line with the 
recent proposition of a common classification framework to 
unify the terminology of NENs arising in different organs 
[46].
MiNENs are neoplasms in which the two components 
are clonally related. Consequently, independent neuroen-
docrine and non-neuroendocrine neoplasms arising in the 
same organ and abutting one another are excluded. For these 
cases, the term “collision tumor” is recommended. Several 
molecular studies have recently demonstrated that MiNENs 




Following the WHO classification [13], digestive MiNENs 
are neoplasms in which the two components are malignant, 
are morphologically and immunohistochemically recogniz-
able, and each of them represents at least 30% of the tumor 
burden (Fig. 8a). However, it is worth noting that the 30% 
cutoff has been chosen arbitrarily and was not based on 
proven clinical evidence [56]. This cutoff was first chosen 
to underline that a minor neuroendocrine component in an 
adenocarcinoma does not influence the prognosis. However, 
in light of recent knowledge and improved morphological 
definitions, it may be critically reconsidered. The fact that 
adenocarcinomas or squamous cell carcinomas with scat-
tered neuroendocrine cells (Fig. 8b), only identifiable with 
immunohistochemistry, cannot be included into the MiNEN 
category does not represent a matter for discussion, since, 
by definition, different tumor components need to be mor-
phologically recognizable and the presence of scattered 
neuroendocrine cells does not have any clinical meaning. 
Conversely, the discussion is open for neoplasms in which 
the two components are recognizable and have a clonal ori-
gin, even when not reaching 30%. They may be considered 
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MiNENs, and this is also justified from a clinical point of 
view, especially when one of the two components is repre-
sented by an aggressive cancer (i.e., NEC), which influences 
the prognosis irrespective of its amount. Consequently, 
the maintenance of the 30% cutoff does not now appear 
mandatory for defining MiNENs. A modern classification 
approach, which takes into account the recent molecular 
knowledge of these neoplasms, may eliminate this rule in 
all cases in which the different tumor components are rec-
ognizable and clonally related [57], as established in other 
organs (i.e., lung) where no minimum percentage of either 
component is required to define a neoplasm as mixed [15].
Mimickers and Differential Diagnosis
The distinction of a MiNENs from an adenocarcinoma with 
interspersed neuroendocrine cells is rather simple because 
the neuroendocrine component is not morphologically rec-
ognizable and neuroendocrine cells are only identified using 
immunohistochemistry.
However, the differential diagnosis of an amphicrine car-
cinoma, which may morphologically resemble a MiNEN, 
may be more problematic. Amphicrine carcinomas, which 
can be found in both digestive and extra-digestive sites, 
are peculiar “hybrid neoplasms” showing morphologi-
cal, immunohistochemical, and ultrastructural features of 
both neuroendocrine and exocrine differentiation in the 
same cells [57]. The hallmark of the differential diagnosis 
resides in the lack of typical organoid and neuroendocrine-
like morphology associated with the co-expression of neu-
roendocrine and non-neuroendocrine markers in the same 
cells. From a clinical point of view, amphicrine carcinomas 
resemble exocrine carcinomas of the same site and recent 
molecular findings demonstrated that they share similarities 
with adenocarcinomas, but not with NENs [58].
Another important differential diagnosis includes the so-
called goblet cell carcinoids of the appendix. A large amount 
of clinical and molecular information has demonstrated that 
these peculiar neoplasms are adenocarcinomas with inter-
spersed neuroendocrine cells and for this reason they are 
now considered a peculiar variant of appendiceal adenocar-
cinoma defined as “goblet cell adenocarcinoma” [59].
The WHO definition of MiNEN does not include neo-
plasms in which the non-neuroendocrine component is 
not malignant, such as an adenoma, due to the negligible 
clinical impact of this component [13]. Such peculiar mixed 
neoplasms can be composed of an adenoma with differ-
ent degrees of dysplasia associated with either a NET of a 
different grade (from G1 to G3) or a NEC. The former are 
indolent neoplasms with no reported tumor-related deaths 
[60], while the latter are highly aggressive neoplasms with 
their behavior related to the NEC component [41]. Recent 
data suggest that mixed neoplasms composed of an ade-
noma associated with either a NET or a NEC are clonally 
related, supporting the speculative possibility to include 
these neoplasms into the MiNEN category [57].
MiNENs of the Lung
Diagnostic Criteria and Classification
In the lung, the term “combined carcinoma” is used to define 
variants of pulmonary NECs and includes two different 
entities: (i) NECs composed of both small and large cell 
NECs and (ii) small or large cell NECs combined with a 
non-neuroendocrine component, irrespective of the amount 
of each component [15]. Unlike the digestive system, com-
bined carcinomas of the lung do not include the rare cases 
in which the neuroendocrine component is represented by 
a NET (carcinoid), which although rare, has been reported 
Fig. 8  Mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN) is a neoplasm in which the two components represent at least 30% of the 
tumor burden A. Adenocarcinoma with interspersed chromogranin-positive neuroendocrine cells B is not considered MiNEN
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in the literature [41]. It has also recently been demonstrated 
that in these peculiar mixed neoplasms, the two components 
are clonally related, suggesting that they should be consid-
ered true mixed neoplasms and not collision tumors [61]. In 
light of these recent findings and in order to be in line with 
the recent proposition of a common classification framework 
to unify the terminology of NENs arising in different organs 
[46], the term combined carcinoma may be critically revised, 
and a change of terminology seems appropriate. Conse-
quently, the term MiNEN can be used to define mixed lung 
neoplasms composed of a neuroendocrine (either NEC or 
NET) and a non-neuroendocrine (adenocarcinoma or squa-
mous cell carcinoma) component, as recently proposed [41].
Mimickers and Differential Diagnosis
As discussed above for MiNENs of the digestive system, 
there are some mimickers that need to be differentiated from 
true lung MiNENs. It is also worth noting that lung ade-
nocarcinomas can show interspersed neuroendocrine cells 
when investigated with immunohistochemistry for general 
neuroendocrine markers, and they should not be considered 
MiNENs. Amphicrine carcinomas of the lung, although rare, 
have been reported, and they do not belong to the MiNEN 
category since they do not show different tumor compo-
nents but are composed of cells showing a neuroendocrine 
and exocrine differentiation in the same cells [62]. From a 
clinical point of view, amphicrine carcinomas of the lung are 
well characterized and further studies are needed to better 
define this entity.
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